The systemic identification and quantification of several metabolic products simultaneously through metabolomics could not only provide diagnosticians with novel sets of diagnostic biomarkers for the disease but also help in quantifying treatment response to medications at an individual level. Along with our technology and expertise, we aim to deliver high-quality metabolomics solutions for diagnostic applications.
The field of metabolomics in which a large number of small molecule metabolites from body fluids or tissues are detected quantitatively in a single step, promises immense potential for early diagnosis, therapy monitoring and for understanding the pathogenesis of many diseases. Analysis of the data from these high-resolution methods using advanced chemometric approaches provides a powerful platform for translational and clinical research, and diagnostic applications.
Our team of experts have been working on many specialized diagnostic tests including early detection of Diabetes, Newborn screening for metabolic disorders and few specialized cancer screening methodologies.
The omics revolution is yielding important new insights into the causes and mechanisms of diseases and drug responses and in understanding the effects of genes and environment in disease predisposition and acquired resistance.
It is paving the way for precision medicine, which focuses its attention on factors specific to an individual patient to provide individualized care; information about a patient’s genes, proteins, and environment is used to prevent, diagnose, and tailor medical care to that of the individual. The use of NGS and omics data is currently revolutionizing how patients are treated.
Personalized medicine (PM) also requires the multidimensionality of disease biomarkers. Our team of scientists and analysts support a systems biology approach integrating omics platform data to develop novel probabilistic models that can be applied to early detection, prognosis, prediction, and prevention.